ENDRA Life Sciences Announces Leadership Changes
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced significant leadership changes. Alexander Tokman, a board member with 24+ years of global commercial leadership experience, has been appointed as acting CEO, replacing Francois Michelon. The company also added two industry veterans to key roles: Ziad Rouag as Head of Regulatory and Clinical Affairs and Richard Jacroux as Chief Financial Officer.
Tokman brings extensive experience in driving revenue growth and implementing improved strategies for startups and established companies. He aims to focus on core regulatory and commercial activities to secure approval and launch ENDRA's patented technology. Rouag's expertise in regulatory affairs will support TAEUS's domestic regulatory process, while Jacroux's financial management experience will aid in scaling the business.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), pioniere della Thermo Acoustic Enhanced UltraSound (TAEUS®), ha annunciato cambiamenti significativi nella leadership. Alexander Tokman, membro del consiglio con oltre 24 anni di esperienza nella leadership commerciale globale, è stato nominato CEO ad interim, sostituendo Francois Michelon. L'azienda ha anche aggiunto due esperti del settore in ruoli chiave: Ziad Rouag come Responsabile degli Affari Regolatori e Clinici e Richard Jacroux come Direttore Finanziario.
Tokman porta con sé una vasta esperienza nella crescita dei ricavi e nell'implementazione di strategie migliorate per startup e aziende consolidate. Si propone di concentrarsi sulle attività regolatorie e commerciali principali per ottenere approvazioni e lanciare la tecnologia brevettata di ENDRA. L'esperienza di Rouag negli affari regolatori supporterà il processo regolatorio domestico di TAEUS, mentre le competenze di gestione finanziaria di Jacroux aiuteranno a scalare l'azienda.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), pionero en la Thermo Acoustic Enhanced UltraSound (TAEUS®), anunció cambios significativos en la dirección. Alexander Tokman, miembro de la junta con más de 24 años de experiencia en liderazgo comercial global, ha sido nombrado CEO interino, reemplazando a Francois Michelon. La compañía también incorporó a dos veteranos de la industria en roles clave: Ziad Rouag como Jefe de Asuntos Regulatorios y Clínicos y Richard Jacroux como Director Financiero.
Tokman aporta una amplia experiencia en la generación de crecimiento de ingresos e implementación de estrategias mejoradas para startups y empresas establecidas. Su objetivo es centrarse en las actividades regulatorias y comerciales clave para asegurar la aprobación y lanzamiento de la tecnología patentada de ENDRA. La experiencia de Rouag en asuntos regulatorios apoyará el proceso regulatorio nacional de TAEUS, mientras que la experiencia financiera de Jacroux ayudará a escalar el negocio.
ENDRA Life Sciences Inc. (NASDAQ: NDRA)는 Thermo Acoustic Enhanced UltraSound (TAEUS®)의 개척자로서 중요한 리더십 변화를 발표했습니다. Alexander Tokman, 전 세계 상업 리더십 경험이 24년 이상인 이사, 가 임시 CEO로 임명되어 Francois Michelon을 대체하게 되었습니다. 이 회사는 또한 두 명의 업계 베테랑을 핵심 역할에 추가했습니다: Ziad Rouag를 규제 및 임상 업무 책임자로, Richard Jacroux를 최고 재무 책임자로 임명했습니다.
Tokman은 스타트업 및 기존 회사에 대한 매출 성장과 개선된 전략 구현에 대한 폭넓은 경험을 갖고 있습니다. 그는 ENDRA의 특허 기술을 승인받고 출시하기 위해 핵심 규제 및 상업 활동에 집중할 계획입니다. Rouag의 규제 업무에 대한 전문성은 TAEUS의 국내 규제 프로세스를 지원하고, Jacroux의 재무 관리 경험은 회사를 성장시키는 데 도움이 될 것입니다.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), un pionnier de la Thermo Acoustic Enhanced UltraSound (TAEUS®), a annoncé des changements significatifs dans sa direction. Alexander Tokman, membre du conseil d'administration avec plus de 24 ans d'expérience en leadership commercial à l'échelle mondiale, a été nommé PDG par intérim, remplaçant Francois Michelon. La société a également ajouté deux vétérans de l'industrie à des postes clés : Ziad Rouag en tant que Responsable des affaires réglementaires et cliniques et Richard Jacroux en tant que Directeur Financier.
Tokman apporte une vaste expérience dans la croissance des revenus et la mise en œuvre de stratégies améliorées pour les startups et les entreprises établies. Il vise à se concentrer sur les activités réglementaires et commerciales fondamentales pour obtenir l'approbation et lancer la technologie (brevettée) d'ENDRA. L'expertise de Rouag en affaires réglementaires soutiendra le processus réglementaire national de TAEUS, tandis que l'expérience de Jacroux en gestion financière aidera à faire évoluer l'entreprise.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), ein Pionier der Thermo Acoustic Enhanced UltraSound (TAEUS®), hat bedeutende Führungswechsel angekündigt. Alexander Tokman, ein Vorstandsmitglied mit über 24 Jahren globaler kommerzieller Führungserfahrung, wurde als amtierender CEO ernannt und ersetzt Francois Michelon. Das Unternehmen hat auch zwei Branchenexperten in Schlüsselpositionen hinzugefügt: Ziad Rouag als Leiter für Regulatorische und Klinische Angelegenheiten und Richard Jacroux als Finanzvorstand.
Tokman bringt umfangreiche Erfahrung in der Umsatzsteigerung und der Umsetzung verbesserter Strategien für Startups und etablierte Unternehmen mit. Er beabsichtigt, sich auf die wesentlichen regulatorischen und kommerziellen Aktivitäten zu konzentrieren, um die Genehmigung zu sichern und die patentierte Technologie von ENDRA auf den Markt zu bringen. Rouags Fachwissen in regulatorischen Angelegenheiten wird den nationalen Regulierungsprozess von TAEUS unterstützen, während Jacroux' Erfahrung im Finanzmanagement dabei helfen wird, das Unternehmen zu skalieren.
- Appointment of Alexander Tokman as acting CEO, bringing 24+ years of global commercial leadership experience
- Addition of Ziad Rouag as Head of Regulatory and Clinical Affairs, strengthening the company's regulatory expertise
- Hiring of Richard Jacroux as Chief Financial Officer, bringing 20+ years of financial management experience
- Renewed focus on core regulatory and commercial activities to secure approval and launch of TAEUS technology
- Departure of former CEO Francois Michelon, potentially causing short-term leadership transition challenges
- Board Member Alexander Tokman appointed as acting CEO bringing 24+ years of global commercial leadership experience
- Two additional industry veterans join in key roles including regulatory and clinical affairs and finance
Mr. Tokman is a growth-driven executive with 24+ years of cross-functional leadership and P&L management experience centered around the development and commercialization of new technology products and services for Medical Device, Biotech, Consumer Electronics, AI and AgTech markets. He has a demonstrated track record in driving breakthrough revenue growth and valuations for start-ups, micro-caps and Fortune 100 companies and implementing improved strategies and operating mechanisms to accelerate business turnarounds.
Prior to ENDRA, he served as a President of a privately held AI/Computer Vision SaaS company and was a CEO-in-Residence at the Allen Institute for Artificial Intelligence (AI2). Mr. Tokman also currently serves as an independent board director for a technology company commercializing a dedicated breast CT imaging platform, and he’s on the board of the American Academy of Thermography, a non-profit organization focused on bringing novel infrared imaging applications for disease diagnosis. Prior to that, he successfully led an IoT technology microcap for over 12 years and spent over 10 years as an executive with GE Healthcare, where he led several global businesses and successful commercialization of multiple business segments, including PET/CT. Mr. Tokman received both undergraduate and graduate Engineering degrees from University of
“As a member of the board, I want to thank Francois for his nine years of faithful service. I am honored to step in and execute on our plan to focus on core regulatory and commercial activities to successfully secure approval and launch our company’s well-patented technology, while exercising a strict fiscal discipline,” said Alexander Tokman, Board Member and acting Chief Executive Officer of ENDRA.
“As we refocus our efforts on the critical company deliverables, I am also excited to welcome Ziad and Richard to ENDRA’s management team to help advance our goal of establishing the TAEUS system as a practical detection and monitoring biomarker solution for metabolic health. Ziad, who previously served as a consultant to ENDRA, brings extensive experience in regulatory affairs and will bolster our internal efforts as we move TAEUS through the domestic regulatory process,” stated Tokman. “Richard is a seasoned financial executive and will be an asset to the Company as we grow and scale the business. Irina Pestrikova, formerly Senior Director, Finance, will help to ensure a smooth transition of daily finance operations to Richard, and remain an advisor to the company as she spends more time with her family.”
Ziad Rouag brings to ENDRA more than two decades of experience in the medical device industry as a leader of clinical operations and regulatory affairs for emerging startups and high-growth businesses. Most recently he served as President and Chief Executive Officer of Biomodex, a digital healthcare company. Prior to Biomodex, Mr. Rouag served as Vice President of Regulatory and Clinical Affairs at several companies including Juul Labs, PQ Bypass and Altura Medical. Mr. Rouag received both a BS and BA from McGill University, and a J.D. from Rutgers University.
Richard Jacroux has over 20 years of experience in financial management and accounting and began his career at Ernst & Young LLP. He has held the role of Chief Financial Officer at several technology companies, is the founder of Impact Solve, LLC, an accounting and fractional chief financial officer service firm and is an adjunct professor at the University of
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology that characterizes tissue similar to an MRI, but at 1/40th the cost and at the point of patient care. TAEUS® is designed to work in concert with the more than 700,000 ultrasound systems in use globally today. TAEUS® is initially focused on the non-invasive assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including non-invasive visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and de novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA’s ability to maintain compliance with Nasdaq listing standards; ENDRA’s dependence on its senior management team; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813604344/en/
Company Contact:
Richard Jacroux
CFO
investors@endrainc.com
www.endrainc.com
Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
Source: ENDRA Life Sciences Inc.
FAQ
Who is the new acting CEO of ENDRA Life Sciences (NDRA)?
What is ENDRA Life Sciences' (NDRA) main technology focus?
Who are the new key appointments at ENDRA Life Sciences (NDRA) besides the acting CEO?
What is the primary goal of ENDRA Life Sciences (NDRA) under the new leadership?
